Vought

Arlington Capital Partners Closes the Acquisition of Triumph’s Composites Business, Forming Qarbon Aerospace

Monday, May 10, 2021 - 12:00pm

b'Arlington Capital Partners (\xe2\x80\x9cArlington\xe2\x80\x9d), a Washington, DC-area private equity firm, today announced it has completed the acquisition of Triumph Group, Inc.\xe2\x80\x99s (NYSE: TGI) composites business.

Key Points: 
  • b'Arlington Capital Partners (\xe2\x80\x9cArlington\xe2\x80\x9d), a Washington, DC-area private equity firm, today announced it has completed the acquisition of Triumph Group, Inc.\xe2\x80\x99s (NYSE: TGI) composites business.
  • Going forward, the business will operate independently as Qarbon Aerospace (the \xe2\x80\x9cCompany\xe2\x80\x9d).\nQarbon Aerospace is a leading provider of large, complex structural components and assemblies such as fuselages, wings, flight control surfaces, and engine nacelles.
  • Qarbon Aerospace has vertically integrated manufacturing capabilities from component fabrication through large-scale assembly as well as proprietary thermoplastics technologies.
  • Arlington is focused on middle market investment opportunities in growth industries including aerospace & defense, government services and technology, healthcare, and business services and software.

Triumph Group to Webcast Fourth Quarter Fiscal Year 2021 Earnings Conference Call Live Webcast scheduled for 8:30 AM ET on May 20, 2021

Tuesday, May 4, 2021 - 10:30pm

b'BERWYN, Pa., May 4, 2021 /PRNewswire/ --Triumph Group, Inc. (NYSE: TGI) will release fourth quarter fiscal year 2021 earnings on May 20, 2021 and will host a conference call that day at 8:30 a.m.

Key Points: 
  • b'BERWYN, Pa., May 4, 2021 /PRNewswire/ --Triumph Group, Inc. (NYSE: TGI) will release fourth quarter fiscal year 2021 earnings on May 20, 2021 and will host a conference call that day at 8:30 a.m.
  • ET.
  • A slide presentation will be included with the audio portion of the webcast.\nGo to the web site at least fifteen minutes early to register, download, and install any necessary audio software.\nFor those who cannot listen to the live broadcast, a replay will be available two hours after the call and will remain available for 90 days.\nTriumph Group, Inc., headquartered inBerwyn, Pennsylvania, designs, engineers, manufactures, repairs and overhauls a broad portfolio of aerospace and defense systems, components and structures.
  • The company serves the global aviation industry, including original equipment manufacturers and the full spectrum of military and commercial aircraft operators.\n'

Regulus Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

Friday, March 5, 2021 - 9:07pm

(Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ("Regulus"), today announced that Jay Hagan, President and Chief Executive Officer of Regulus, will present at the H.C. Wainwright Global Life Sciences Conference being held virtually on March 9-10, 2021.

Key Points: 
  • (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ("Regulus"), today announced that Jay Hagan, President and Chief Executive Officer of Regulus, will present at the H.C. Wainwright Global Life Sciences Conference being held virtually on March 9-10, 2021.
  • A webcast of the on-demand presentation will be available beginning Tuesday, March 9, 2021 through the investor relations section of the Company's website at www.regulusrx.com .
  • These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect.
  • These and other risks are described in additional detail in Regulus' filings with the Securities and Exchange Commission.

Regulus Group, LLC Wins the Federal Aviation Administration's (FAA) Program Support Services (PSS) Contract

Tuesday, February 9, 2021 - 1:30pm

WOODSTOCK, Va., Feb. 9, 2021 /PRNewswire/ --Regulus Group, LLC, a high technology small business firm specializing in air traffic management systems and services, was the only small business awarded a prime contract by the FAA for the Program Support Services (PSS) contract.

Key Points: 
  • WOODSTOCK, Va., Feb. 9, 2021 /PRNewswire/ --Regulus Group, LLC, a high technology small business firm specializing in air traffic management systems and services, was the only small business awarded a prime contract by the FAA for the Program Support Services (PSS) contract.
  • Regulus Group along with their teammates will provide technical and professional services primarily to the FAA's Program Management Organization's (PMO) directorates and programs.
  • Regulus Group assembled an expert team of subcontractors to secure this contract with innovative approaches that will advance the FAA's mission.
  • Regulus Group, LLC is a renowned integrator of air traffic systems and services for the FAA and Department of Defense (DoD).

Regulus Global Hurricane Preparedness Equipment Now Aids in COVID-19 Response for the Bahamas

Monday, February 8, 2021 - 2:00pm

In support of the U.S. Department of Defense's Northern Command (NORTHCOM) and the U.S. Embassy in Nassau, Bahamas, Regulus Global built, integrated and delivered a $3.5 million modular shelter and hygienic solution system.

Key Points: 
  • In support of the U.S. Department of Defense's Northern Command (NORTHCOM) and the U.S. Embassy in Nassau, Bahamas, Regulus Global built, integrated and delivered a $3.5 million modular shelter and hygienic solution system.
  • The modular units provide immediate shelter, kitchen and sanitary necessities for displaced citizens and/or disaster response personnel in the wake of a hurricane or natural disaster.
  • "In 30 days, Regulus Global designed, developed and delivered a hurricane response system to the Bahamas; and that is just one example of our team's unwavering focus on pragmatic humanitarian solutions," said Brad Stewart, director of innovation and design solutions, Regulus Global.
  • Regulus Global , a leader in innovative design, enables capability from initial requirement through delivery to sustainment.

Regulus Announces Addition to Board of Directors

Wednesday, January 27, 2021 - 1:07pm

Concurrently with her appointment to the Board, Dr. Huang was appointed to serve on the Compensation Committee.

Key Points: 
  • Concurrently with her appointment to the Board, Dr. Huang was appointed to serve on the Compensation Committee.
  • "We are pleased to add Dr. Huang to the Regulus board.
  • We believe her extensive scientific background will be of benefit to helping direct the Company's drug discovery and development programs," said Stelios Papadopoulos, Ph.D., Chairman of the Board of Directors of Regulus.
  • Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs.

Triumph Group to Webcast Third Quarter Fiscal Year 2021 Earnings Conference Call

Friday, January 15, 2021 - 3:49am

BERWYN, Pa., Jan. 14, 2021 /PRNewswire/ --Triumph Group, Inc. (NYSE: TGI) will release third quarter fiscal year 2021 earnings on February 3, 2021 and will host a conference call that day at 8:30 a.m.

Key Points: 
  • BERWYN, Pa., Jan. 14, 2021 /PRNewswire/ --Triumph Group, Inc. (NYSE: TGI) will release third quarter fiscal year 2021 earnings on February 3, 2021 and will host a conference call that day at 8:30 a.m.
  • A slide presentation will be included with the audio portion of the webcast.
  • Go to the web site at least fifteen minutes early to register, download, and install any necessary audio software.
  • Triumph Group, Inc., headquartered inBerwyn, Pennsylvania, designs, engineers, manufactures, repairs and overhauls a broad portfolio of aerospace and defense systems, components and structures.

Chris Blair to Join Radius Aerospace as Head of Business Development

Tuesday, January 5, 2021 - 6:25pm

Radius Aerospace, Inc. (Radius or the Company) announced today that Chris Blair has joined the executive leadership team as Head of Business Development.

Key Points: 
  • Radius Aerospace, Inc. (Radius or the Company) announced today that Chris Blair has joined the executive leadership team as Head of Business Development.
  • In this role, Blair will oversee major customer relationships and Radius new business development and sales functions, and help guide the Company on its continued growth trajectory.
  • Blair brings over 23 years of business development expertise to Radius.
  • Prior to Incora, Blair served in various executive level capacities at Triumph Group, where he served as the Head of Aerostructures Business Development and VP of Corporate Business Development.

Regulus Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference

Tuesday, January 5, 2021 - 1:07pm

(Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ("Regulus"), today announced that Jay Hagan, President and Chief Executive Officer of Regulus, will present at the H.C. Wainwright Virtual BioConnect Conference being held from January 11-14, 2021.

Key Points: 
  • (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ("Regulus"), today announced that Jay Hagan, President and Chief Executive Officer of Regulus, will present at the H.C. Wainwright Virtual BioConnect Conference being held from January 11-14, 2021.
  • A webcast of the on-demand presentation will be available beginning Monday, January 11, 2021 through the investor relations section of the Company's website at www.regulusrx.com .
  • These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect.
  • These and other risks are described in additional detail in Regulus' filings with the Securities and Exchange Commission.

Regulus Therapeutics Collaborates With Bio-Techne For Biomarker Development

Wednesday, December 2, 2020 - 12:00pm

MINNEAPOLIS, Dec. 2, 2020 /PRNewswire/ --Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics (NASDAQ: RGLS) announced a collaboration to support Regulus with biomarker analysis for the clinical development of RGLS4326, an Autosomal Dominant Polycystic Kidney Disease (ADPKD) treatment.

Key Points: 
  • MINNEAPOLIS, Dec. 2, 2020 /PRNewswire/ --Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics (NASDAQ: RGLS) announced a collaboration to support Regulus with biomarker analysis for the clinical development of RGLS4326, an Autosomal Dominant Polycystic Kidney Disease (ADPKD) treatment.
  • Regulus has utilized two Bio-Techne branded product lines, ProteinSimple and Exosome Diagnostics, to aid in their clinical trial patient testing.
  • Regulus has elected to collaborate with Bio-Techne for the development of high-performance biomarker assays to support the assessment of PC1 and PC2 levels using the fully automated Simple Western instrument as a read-out.
  • "Regulus is pleased to enter this collaboration with Bio-Techne," said Jay Hagan, Chief Executive Officer of Regulus.